Abecma and cilta cel are part of an emerging class of multiple myeloma treatments that target a protein called BCMA, which is found on cancer …

SGS has just completed a significant expansion project at its Glasgow facility, meaning it can provide increased biosafety testing for the biologics, drug development, and …

Adaptimmune, like companies such as Bluebird Bio and Cellectis, remains one of the more prominent independent developers of cancer cell therapies. Early pioneers Kite Therapeutics …